Liquidity & Technical

Liquidity & Technical

Onyx Biotec is an NSE SME Emerge listing with no usable volume in the public tape — over 389 trading sessions since the November 2024 IPO, every single record carries zero reported volume, so institutional sizing math collapses to a wall. The tape itself is unambiguous: price has bled from a ₹90 first-month spike to ₹32 today, sitting fifteen percent below the 200-day moving average, seven percent off the 52-week low, with momentum just rolling over again from a brief mid-May bounce.

1. Portfolio implementation verdict

2. Price snapshot strip

Beta is not computable — the relative-performance dataset includes no comparable benchmark series for this name, so a regression slope would be statistically meaningless. The 52-week position field (7.3 out of 100) is the cleaner single readout: the stock is parked at the floor of its annual range and twenty-five percent below the 200-day average.

3. The critical chart: full-history price with 50/200 SMA

Price is below the 200-day moving average (₹37.66) by fifteen percent and has never traded above it. The 50-day broke decisively under the 200-day in late August 2025 once the 200-day had enough history to compute, and the two lines have only widened since — there has been no golden cross, only one continuous downtrend regime from the ₹90 January 2025 peak.

4. Relative strength vs benchmark + sector

No usable benchmark series is available for this ticker. The price data exists only since the November 2024 IPO, the relative-performance dataset contains zero matched benchmark rows, and no Indian-pharma sector basket has been rebased alongside it. A standalone "company rebased to 100" line on its own conveys no relative information that the price chart above does not — so we skip this anchor rather than fabricate one.

5. Momentum panel — RSI + MACD

RSI is at 32.5 — weak, but not yet the kind of capitulation oversold (sub-15) the stock has registered four times in this history. The MACD histogram has just flipped negative again (−0.22) after a brief positive run in late April through mid-May, killing the second-derivative case for the May bounce. There is no constructive divergence anywhere in the recent tape: RSI peaks have been falling (78 in early-April → 67 in early-May → 33 now) while price retraced from ₹35 back to ₹32. Both indicators say the same thing: near-term direction is still down, but the magnitude is decaying, and another mechanical oversold print in the next two to three weeks is plausible.

6. Volume, volatility, and sponsorship

The source price feed reports zero traded volume on every one of the 389 sessions since the IPO — this is a known data-capture gap for NSE SME Emerge tickers rather than a literal claim that nothing traded, but it means we cannot construct a volume bar chart, a volume-confirms-trend test, or a ranked unusual-volume table. The unusual_volume.json artefact correctly returns zero spikes. What this tells you operationally is more important than the chart we are not drawing: no third-party data vendor that institutions key off of is publishing usable sponsorship signal for this name, so any "smart money is accumulating" narrative would have to be reconstructed from filings, not from tape.

Realized vol bands across this history sit at p20 = 16.8%, p50 = 20.2%, p80 = 26.7%. Today's 17.2% sits just above the calm-regime threshold and well below the levels reached during the January 2025 IPO mania (60%) or the January 2026 quarterly print blow-up (39%). Calm vol in a downtrend is not a contrarian buy signal — it is a stock no one is fighting over.

7. Institutional liquidity panel

Days-to-exit cells are blank by design: dividing position shares by zero ADV is mathematically undefined, and quoting a number would imply false precision. The intraday-range proxy is also zero in the source (each session prints a single value), so we cannot estimate impact cost from public data either — anyone genuinely seeking exposure would need to negotiate block deals directly with sellers, not work the screen.

The largest size that clears the conventional five-day-at-20%-ADV institutional threshold is, on paper, zero shares. The practical answer is that any meaningful institutional accumulation in this name requires patient counterparty sourcing measured in weeks-to-quarters rather than days, and any premium-priced research process that treats this as a tradable line item is overstating its own capacity.

8. Technical scorecard + stance

Stance: bearish on the 3-to-6-month horizon. The dominant signal is a regime in which price has not once reclaimed its own 200-day moving average since the indicator became computable, every momentum bounce has been sold within five to ten sessions, and the floor at the ₹30.30 all-time low has been tagged but not held convincingly. Two levels matter: reclaiming and holding above ₹38 (the 200-day SMA) would be the first technical evidence of a regime change worth respecting; a daily close below ₹30 (the all-time and 52-week low) opens space to retest the IPO-era unwind levels in the high-₹20s with no chart support before that. Liquidity is the constraint. Even if the tape turned, the appropriate action for any institutional reader is watchlist-only — there is no public-market path to building a position at a respectable cost basis, and any decision to act would have to come through filings, primary diligence, and direct block sourcing rather than from anything visible in the price chart.